ALASTIN Restorative Skin Complex: the current TriHex+ serum

The current product page calls Restorative Skin Complex with TriHex+ a peptide serum and gives its size as 1 fl oz, or 29.6 mL. It describes targets including texture, tone, volume, hydration and elasticity. The technology page separately lists this exact named item at $258.

The displayed price is a manufacturer offer detail from the source date, without a completed transaction or stock check. More importantly, TriHex+ is part of the present product identity. A reader finding older material about Restorative Skin Complex should check whether it addresses this version. An unchanged family name is not sufficient evidence that an older formula, study or photograph belongs to the current serum.

The product’s posted ingredients include niacinamide, several individually named peptides, Octapeptide-45, Magnolol and other components. ALASTIN describes TriHex+ as enhanced with its proprietary Octapeptide-45 and links Magnolol with its account of facial volume. These are attributed manufacturer explanations, not independent measurements of the serum’s biological activity.

The full list is useful because it lets a reader see named components beyond the branded complex. It still does not state their concentrations or assign a share of the outcome to each ingredient. Reading Octapeptide-45 in a declaration confirms what the manufacturer lists; it does not establish how much reaches a target, how it performs in this preparation or the amount of visible change a person can expect.

ALASTIN describes improved hydration alongside changes in the appearance of plumpness, volume and elasticity. Its current benefit account connects these ideas with TriHex+ and Magnolol. A reader can recognize the intended benefits while asking which of them was actually measured and how.

The hydration-versus-firmness discussion is useful here because a more hydrated-looking surface and a sustained change in facial fullness are different claims. The declaration alone does not settle either result. Nor does a description of an ingredient supporting a natural process quantify what this whole serum changed. The evidence question should match the desired outcome, rather than treating the word volume as an assurance of a particular contour change.

In its 12-week clinical summary, ALASTIN says 98% agreed that hydration improved, 89% reported better overall texture and 93% reported overall satisfaction. These are separate reported endpoints. Satisfaction is not a numerical measure of wrinkle depth, and agreement about hydration does not establish a measured increase in facial volume.

The returned summary does not provide the participant denominator or a complete protocol. A photograph identifies a woman aged 59 and attributes data to ALASTIN, with a notice that results vary. Her age is not a count of study participants. No full underlying report was acquired, so the displayed percentages remain the manufacturer’s summary, without an independently read account of recruitment, comparisons or the methods behind each result.

The technology explanation describes a proprietary platform used across anti-aging and procedure-care products. Its reference list includes an eye treatment, a body product associated with procedures, and a regimen used with radiofrequency microneedling. Those are identifiable subjects in the bibliography, not evidence that every reference tested the current facial serum.

No full papers from that list were obtained for this review. The distinction matters even where a technology name is shared: the preparation, population, comparison and outcome may differ. The wider research can explain the brand’s rationale for the platform. It cannot, from the reference titles alone, supply missing methods for the current TriHex+ serum’s hydration or texture percentages, or validate an unrelated procedural result for everyday facial appearance care.

The serum description discusses natural production of collagen, elastin and hyaluronic acid. FDA’s intended-use guidance explains why claims about affecting body structure or function involve a different regulatory question from ordinary beautifying claims. This review does not determine a regulatory status for the serum from marketing wording alone.

For readers arriving through an estriol search, the distinction is also practical: this named retail serum is not being presented here as a prescription estrogen treatment. The estriol guide covers that ingredient’s separate identity. Neither TriHex terminology nor a product’s placement among appearance-care alternatives answers a clinician’s question about an individual’s hormone treatment, medical history or expected treatment benefit.

A useful clarification would identify the number of participants and the exact assessment behind each current TriHex+ percentage. The product summary provides a recognizable version and selected outcomes; the platform material gives a broader research story. Keeping those roles distinct is more informative than combining every mention of TriHex into one evidence claim.

The NEOCUTIS article and CeraVe article offer other product-specific reading questions, while the comparison guide locates retail products beside the prescription category. These are navigation options, not a performance ranking. For this serum, a current-version report would make the reported hydration and texture results much easier to interpret.